# Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

> **NCT06985706** · PHASE3 · RECRUITING · sponsor: **Belfast Health and Social Care Trust** · enrollment: 264 (estimated)

## Conditions studied

- Severe Diabetic Macular Oedema

## Interventions

- **PROCEDURE:** Subthreshold Micropulse Laser (SML)
- **DRUG:** Anti-VEGF Monotherapy (standard care)

## Key facts

- **NCT ID:** NCT06985706
- **Lead sponsor:** Belfast Health and Social Care Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-19
- **Primary completion:** 2028-11-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06985706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06985706, "Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06985706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*